LFB-SA
18.4.2016 15:39:14 CEST | Business Wire | Press release
Key events in 2015 :
- Launched a new generation plant financed by a €230 million capital increase, fully underwritten by the French State, currently the sole shareholder of LFB.
- Two new products registered in Europe
- Significant investment in R&D with €81.3 million* owing to several products currently in phase III trials
- Gross margin in decline as compared to 2014 due to the production of commercial batches for phase III products
- Turnover of €502.4 million, stable in comparison to 2014
Christian Béchon, Chief Executive Officer of L.F.B S.A. declared:
"In
2015, the key milestones have been successfully achieved. It has been a
historic and productive year for the future of LFB."
An unprecedented increase in capital in order to finance the group's
development
As part of the group's strategic development, LFB's
shareholder (the French State) decided in October to underwrite an
increase in LFB's share capital by €230 million. The share capital of
the company now stands at €280 million. To meet the financing needs of
LFB's development project, on 5 January 2016 LFB issued a senior bond of
€124 million. These funds will enable the construction of a 'new
generation' plant in Arras. This flagship project, representing an
investment of approximately €300 million, will enable LFB to triple its
global production capacity in 2020 with facilities aimed at
manufacturing for the whole world.
LFB is also developing its sites
in Alès (Gard) and Charlton (USA), establishing bio-production
facilities for recombinant medicines in development.
|
Consolidated earnings in €M |
2015 | 2014 | Variation 2015/2014 | |||
|
Turnover |
502.4 |
501.9 |
0.1 % |
|||
|
Gross margin |
177.6 |
195.5 |
-9.2 % |
|||
|
Research & development |
(81.3) |
(65.9) |
||||
|
Commercial costs |
(51.0) |
(48.6) |
||||
|
General costs |
(50.3) |
(48.7) |
||||
|
Other charges and |
17.0 |
(7.1) |
||||
|
Operational earnings |
12.0 |
25.2 |
||||
|
as a % of turnover |
2.4 % |
5.0 % |
||||
|
Net earnings |
0.3 |
13 |
€90.5 million* before research tax credit
2015 turnover - growth in international sales
At €502.4
million, turnover is relatively stable as compared to 2014. For the
second successive year, the group's turnover exceeded €500 million, with
the international side business continuing to grow. Despite a 3.2 %
decline in turnover in France during 2015, international sales rose by
€12.1 million (+8.7%), reaching €152 million. This figure represents 30%
of consolidated turnover (28% in 2014).
Operational earnings decline in order to finance strategy
Research
and development costs are increasing rapidly (€81.3 million), owing to
the large number of phase III trials in progress. Various strategic
projects reached significant milestones. In 2015, two new LFB products,
a 10% immunoglobulin and a fibrinogen have been subject to a mutual
recognition in procedure in Europe with the Paul Ehrlich Institute as
the referral agency. Two other recombinant products are currently at the
end of phase III. At the same time, LFB is planning to manufacture
product batches for launch, which has had an impact on earnings. In
2015, the group posted encouraging operational income (€17 million),
notably owing to its holding in the bio-tech company TG Therapeutics
Inc. The positive operational earnings (€12.0 million) is down as
compared to that of 2014 (-13.2 million) due to a decline in gross
margins and increased development costs. Despite this unprecedented
effort, net earnings remain positive at €0.3 million.
About LFB Group
LFB is a
bio-pharmaceutical company that develops, manufactures, and markets
medicinal products from living systems for the treatment of serious and
often rare diseases in the fields of Immunology, Hemostasis, Perinatal,
and Intensive Care. Currently ranked 6th worldwide in the field of
plasma-derived medicinal products, LFB Group is also among the leading
European companies in the development and production of proteins and
innovative treatments derived from bio-technologies. It employs 2,111
staff worldwide.
http://www.groupe-lfb.fr
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160418005971/en/
Contact:
LFB SA
Sandrine Charrières, 01.69.82.72.80
Communication
Director
charrieres@lfb.fr
or
David
Loison, 01.69.82.70.20
Financial Affairs Director
loisond@lfb.fr
or
Havas
Worldwide
Jeanne Bariller, 06.15.51.49.40
jeanne.bariller@havasww.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom